Clinical Trial Update: AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) [Phase 1, Phase 2]

View source ↗

Summary

Arsenal Biosciences reports an ongoing Phase 1/2 clinical trial of AB-2100, an integrated circuit T cell therapy, in patients with recurrent advanced/metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• AB-2100

Snippet

Sponsor: Arsenal Biosciences, Inc. | Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING